Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Receives NY State Clearance for Second-Gen Test for Cancer of Unknown Primary

Premium

Rosetta Genomics said this week that the New York State Department of Health has approved the company's miRview Mets 2 microRNA diagnostic, which is used to detect the source of cancers of unknown primary origin.

New York is the only state that requires an independent regulatory review for laboratory-developed tests, Rosetta noted.

With the approval, Rosetta said it can now market the test in all 50 US states.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.